Want to see PL:CTX full AI Analyst Report?

Captor Therapeutics SA (CTX) Price & Analysis

1 Followers

CTX Stock Chart & Stats

zł42.20

Market closed

zł42.20

Day’s Range― - ―

52-Week Rangezł33.00 - zł89.20

Previous CloseN/A

VolumeN/A

Average Volume (3M)15.34K

Market Cap

zł475.23M

Enterprise Valuezł482.18M

Total Cash (Recent Filing)zł17.89M

Total Debt (Recent Filing)zł3.19M

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Sep 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.72

Shares Outstanding6,353,397

10 Day Avg. Volume10,947

30 Day Avg. Volume15,340

Financial Highlights & Ratios

PEG Ratio1.22

Price to Book (P/B)16.92

Price to Sales (P/S)85.26

P/FCF Ratio-10.88

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-3.4

Revenue Forecast (FY)zł52.13M

Bulls Say, Bears Say

Bulls Say

Proprietary Technology PlatformCaptor Therapeutics' TPD platform offers a unique approach to drug development, potentially providing a competitive edge in creating novel therapies for oncology and autoimmune diseases.

Strategic PartnershipsStrategic partnerships provide funding and potential revenue streams, supporting R&D efforts and enhancing the company's ability to advance its drug candidates through clinical trials.

Revenue DiversificationLicensing agreements diversify revenue streams, reducing reliance on a single income source and potentially increasing financial stability as the company progresses in its development pipeline.

Bears Say

Declining RevenueA significant decline in revenue growth poses a challenge to financial sustainability, impacting the company's ability to fund operations and invest in future growth opportunities.

Negative Cash FlowConsistent negative cash flows limit financial flexibility, potentially hindering the company's capacity to invest in R&D and scale its operations effectively.

Profitability ChallengesOngoing profitability issues, such as negative net profit margins, highlight operational inefficiencies and may affect long-term viability if not addressed.

CTX FAQ

What was Captor Therapeutics SA’s price range in the past 12 months?

Captor Therapeutics SA lowest stock price was zł33.00 and its highest was zł89.20 in the past 12 months.

What is Captor Therapeutics SA’s market cap?

Captor Therapeutics SA’s market cap is zł475.23M.

When is Captor Therapeutics SA’s upcoming earnings report date?

Captor Therapeutics SA’s upcoming earnings report date is Sep 03, 2026 which is in 58 days.

How were Captor Therapeutics SA’s earnings last quarter?

Currently, no data Available

Is Captor Therapeutics SA overvalued?

According to Wall Street analysts Captor Therapeutics SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Captor Therapeutics SA pay dividends?

Captor Therapeutics SA does not currently pay dividends.

What is Captor Therapeutics SA’s EPS estimate?

Captor Therapeutics SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Captor Therapeutics SA have?

Captor Therapeutics SA has 6,353,397 shares outstanding.

What happened to Captor Therapeutics SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Captor Therapeutics SA?

Currently, no hedge funds are holding shares in PL:CTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Captor Therapeutics SA

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.